NEW YORK – The US Food and Drug Administration on Thursday approved the combination of three Genentech drugs, the immune checkpoint inhibitor atezolizumab (Tecentriq), the MEK inhibitor cobimetinib (Cotellic), and the BRAF inhibitor vemurafenib (Zelboraf), for the treatment of BRAF V600-mutated advanced melanoma.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.